Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Global Symmetry: Cyclic - C2  (3D View)
Global Stoichiometry: Homo 2-mer - A2 

Biological assembly 1 assigned by authors and generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 60.28 kDa 
• Atom Count: 4086 
• Residue Count: 495 
• Unique protein chains: 1

6DXK

Glucocorticoid Receptor in complex with Compound 11

• DOI: 10.2210/pdb6DXK/pdb

• Classification: TRANSCRIPTION
• Organism(s): Homo sapiens
• Expression System: Escherichia coli
• Mutation(s): Yes 


• Deposited: 2018-06-29 Released: 2018-10-03 
• Deposition Author(s): Rew, Y., Du, X., Eksterowicz, J., Zhou, H., Jahchan, N., Zhu, L., Yan, X., Kawai, H., McGee, L.R., Medina, J.C., Huang, T., Chen, C., Zavorotinskaya, T., Sutimantanapi, D., Waszczuk, J., Jackson, E., Huang, E., Ye, Q., Fantin, V.R., Daqing, S.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 3.05 Å
• R-Value Free: 0.260 
• R-Value Work: 0.217 
• R-Value Observed: 0.218 

Literature

Discovery of a Potent and Selective Steroidal Glucocorticoid Receptor Antagonist (ORIC-101).

Rew, Y., Du, X., Eksterowicz, J., Zhou, H., Jahchan, N., Zhu, L., Yan, X., Kawai, H., McGee, L.R., Medina, J.C., Huang, T., Chen, C., Zavorotinskaya, T., Sutimantanapi, D., Waszczuk, J., Jackson, E., Huang, E., Ye, Q., Fantin, V.R., Sun, D.

(2018) J Med Chem 61: 7767-7784

• PubMed: 30091920 
• DOI: 10.1021/acs.jmedchem.8b00743
• Primary Citation of Related Structures:  
  6DXK


• PubMed Abstract: 
  

The glucocorticoid receptor (GR) has been linked to therapy resistance across a wide range of cancer types. Preclinical data suggest that antagonists of this nuclear receptor may enhance the activity of anticancer therapy. The first-generation GR antagonist mifepristone is currently undergoing clinical evaluation in various oncology settings. Structure-based modification of mifepristone led to the discovery of ORIC-101 (28), a highly potent steroidal GR antagonist with reduced androgen receptor (AR) agonistic activity amenable for dosing in androgen receptor positive tumors and with improved CYP2C8 and CYP2C9 inhibition profile to minimize drug-drug interaction potential. Unlike mifepristone, 28 could be codosed with chemotherapeutic agents readily metabolized by CYP2C8 such as paclitaxel. Furthermore, 28 demonstrated in vivo antitumor activity by enhancing response to chemotherapy in the GR ⁺ OVCAR5 ovarian cancer xenograft model. Clinical evaluation of safety and therapeutic potential of 28 is underway.

---

Organizational Affiliation: 

ORIC Pharmaceuticals , 240 East Grand Avenue, Fl2 , South San Francisco , California 94080 , United States.

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Glucocorticoid receptor	A, B	258	Homo sapiens	Mutation(s): 9  Gene Names: NR3C1, GRL
Find proteins for P04150 (Homo sapiens) Explore P04150  Go to UniProtKB:  P04150
NIH Common Fund Data Resources
PHAROS:  P04150 GTEx:  ENSG00000113580

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
HJ4	A, B	(8S,11R,13S,14S,17S)-11-[4-(dimethylamino)phenyl]-17-(3,3-dimethylbut-1-yn-1-yl)-17-hydroxy-13-methyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one (non-preferred name) C32 H41 N O2 MKYOYWSMPLRHDW-SSKMXYOESA-N

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 3.05 Å
• R-Value Free: 0.260 
• R-Value Work: 0.217 
• R-Value Observed: 0.218 
• Space Group: P 2₁ 2₁ 2₁

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 79.193	α = 90
b = 98.694	β = 90
c = 100.41	γ = 90

Software Package:

Software Name	Purpose
REFMAC	refinement
XDS	data reduction
XSCALE	data scaling
PHASER	phasing

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2018-06-29 
• Released Date: 2018-10-03 
Deposition Author(s): Rew, Y., Du, X., Eksterowicz, J., Zhou, H., Jahchan, N., Zhu, L., Yan, X., Kawai, H., McGee, L.R., Medina, J.C., Huang, T., Chen, C., Zavorotinskaya, T., Sutimantanapi, D., Waszczuk, J., Jackson, E., Huang, E., Ye, Q., Fantin, V.R., Daqing, S.

Revision History 

• Version 1.0: 2018-10-03
  Type: Initial release